

## Reference Citations

The following are the research citations that are cited in all of the articles found on the Psychmedfacts.com website. Citations are organized by the number found in the texts of the articles.

1. Congressional Budget Office. *Research on the Comparative Effectiveness of Medical Treatments: Issues and Options for an Expanded Federal Role*. December, 2007.
2. Assessing the Efficacy and Safety of Medical Technologies September 1978 NTIS order #PB-286929
3. McGlynn, EA., Asch, SM., Adams, J., Keesey, J., Hicks, J., Cristofaro, A., & Kerr, EA. (2003). The quality of health care delivered to adults in the united states. *The New England Journal of Medicine*, 348, 26, 2635-2645.
4. Kunen, S., Niederhauser, R., Smith, P., Morris, J. A., & Marx, B. (2005). Race disparities in psychiatric rates in emergency departments. *Journal of Consulting and Clinical Psychology*, 73 (1), pp. 116-126.
5. Morris, J. A. (Ed.) (1997). *Practicing Psychology in the Rural Setting: Hospital Privileges and Collaborative Care*. Washington, DC: *American Psychological Association*.
6. Morris, J.A. (2007). Caring for the Poor, NAPPP Home Page/Position Papers, <http://www.nappp.org/positions.html> 2010
7. Kroenke, K., & Manglesdorff, D. (1989). Common symptoms in ambulatory care: Incidence, evaluation, therapy, and outcome. *American Journal of Medicine*, 86, pp. 262-266.
8. Antonuccio, D. O., Burns, D. D., & Danton, W. G. (2002). Antidepressants: A triumph of marketing over science? *Prevention & Treatment*, 5, Article 25. Available on the World Wide Web: <http://www.journals.apa.org/prevention/volume5/pre525c.html>.

9. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. *PLoS Med*;5:e45.
10. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med*;358:252-60.
11. Thase ME, Friedman ES, Berman SR, et al (2000). Is cognitive behavior therapy just a 'nonspecific' intervention for depression? A retrospective comparison of consecutive cohorts treated with cognitive behavior therapy or supportive counseling and pill placebo. *J Affect Disord.*; 57: 63-71
12. Antonuccio, D. O., Danton, W. G., DeNelsky, G. Y., Greenberg, R. P., & Gordon, J. S. (1999). Raising questions about antidepressants. *Psychotherapy and Psychosomatics*, 68, 3–14.
13. Institute of Medicine (U.S.), (2006). National Academies of Science, Advising the Nation. Improving Health. *Improving the Quality of Health Care for Mental and Substance-Use Conditions: Quality Chasm Series*. <http://www.nap.edu/catlog/11470>. Pages 1-504.
14. Greenfield, Susan, (1995). Journey to the Centers of the Mind. W. H. Freeman and Company, New York, New York.
15. Schwartz, Jeffery, and Begley, Sharon (2002). The Mind & The Brain: Neuroplasticity and the Power of Mental force. HarperCollins Publishers, New York, New York.
16. Szasz, Thomas (1920). Schizophrenia: The Sacred Symbol of Psychiatry. Basic Books, Inc., New York, New York.
16. Hobson, J. A., and Leonard, J. A. (2001). Out of Its Mind: Psychiatry in Crisis, A Call for Reform. Perseus Books Group, Cambridge MA.
17. Stein, D. B. (1999). Ritalin is Not the Answer: A Drug-Free, Practical Program for Children Diagnosed with ADD or ADHD. John Wiley & Sons, Inc, New York, New York.

18. Glasser, William (2003). *Warning: Psychiatry Can Be Hazardous to Your Mental Health*. HarperCollins Publishers Inc., New York, New York
19. Glasser, William (1984). *Control Theory: Anew Explanation of How We Control Our Lives* Harper & Row Publishers Inc., New York, New York.
20. Cohen, C. I. (1993). The biomedicalization of psychiatry: A critical over view. *Community mental Health Journal*, 29, 509-521.
21. Cornwell, John (1996). *The Power to Harm: Mind, Medicine, and Murder on Trial*. Penguin Books USA Inc., New York, New York.
22. Goozner, Merrill (2004). *The \$800 Million Pill: The Truth Behind the cost of New Drugs*. University of California Press, Berkley and Los Angeles, California.
23. Volpicelli, J. R., Pettinati, H. M., McLellan, A. T., O'Brien, C. P. (2001). *Combining Medication and Psychosocial Treatment for Addictions*. Guilford Press, New York, New York.
24. Prosky, P. S., and Keith, D. V. (Eds., 2003). *Family Therapy as an Alternative to Medication: An Appraisal of Pharmland*. Brunner-Routledge, New York, New York.
25. Miklowitz, David (2006). Psychosocial Interventions in Bipolar Disorders: Rationale and Effectiveness. In *Bipolar Psychopharmacotherapy: Caring for the Patient*. John Wiley & Sons, Ltd., West Sussex, England. Page: 313-345.
- 25a. CDC report: <http://www.cdc.gov/mmwr>
26. Sink, K. M., Holden, K. F., & Yaffe, K. (2005). Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia. *JAMA*, 293(5), 596-608.
27. Reed, G. A., & Del Ponte, P. (2002). Medical Never-Never Land: 10 Reasons Why America is Not Ready for the Coming Age Boom. *The Alliance For Aging Research*. Retrieved April 20, 2002. Retrieved from <http://www.agingresearch.org/contentarticle/detail/898>

28. United States Senate Special Committee on Aging. (2009, Wednesday, January 14, 2009). *Bolstering Workforce Will Be Integral Part of National Health Care Reform* [Press release]. Retrieved from <http://aging.sena>
29. Comin, Linda (2009). Geriatric State of Emergency. *The Clinical Practitioner*. April, 2010. Published by the National Alliance of Professional Psychology Providers.
30. Morris, J.A. (2008). The War on Psychotherapy. *The Clinical Practitioner*. February , 2010. Published by the National Alliance of Professional Psychology Providers.
31. Agency for Healthcare Research and Quality. Reducing and preventing adverse drug events to decrease hospital costs. *Research in Action*, 2001; Issue 1. Number 01-0020, March, Agency for Healthcare Research and Quality, Rockville, MD.
32. Woodcock, J. Testimony on medical errors: Understanding adverse drug events. Before the senate Committee on Health, Education, Labor, and Pensions. February 1, 2000.
33. Wachter, RM. Making health care safer: A critical analysis of patient safety practices. 1997; University of California at San Francisco-Stanford University Evidence-Based Practice Center, AHRQ Contract No. 290-0013.
34. Quality of Health care in America: Institute of Medicine.(2000). *To Err Is Human: Building a safer health system*. Washington, D.C., National Academy Press.
35. Schenkel, S. (2001). Promoting patient safety and preventing medical error in emergency departments. *Academic Emergency Medicine*, 7, 1204-1222.
36. Aparasu, RR. (1999). Visits to office-based physicians in the United States for medication-related morbidity. *Journal of the American Pharmacy Association*, 39, 3, 332-337.
37. Tamblyn, RM., McLeod, PJ., Abrahamowicz, M., & Laprise, R. (1996). Do too many cooks spoil the broth? Multiple physician involvement in medical management of elderly patients and potential inappropriate drug combinations. *CMAJ*, 154, 8, 1177-1184.

38. Brennan TA, Leape LL & Laird, NM. (1991). Incidence of adverse events and negligence in hospitalized patients. *New England Journal of Medicine*, 324, 370 -376.
39. Leape LL, Lawthers AG, Brennan TA, Johnson WG. (1993). Preventing medical injury. QRB *Quality Review Bulletin*, 19, 144 –149.
40. McIntyre, J., Conroy, S., Avery, A., Corns, H., & Choonara, I. (2000). Unlicensed and off label prescribing of drugs in general practice. *Arch Dis Child*, 83, 498-501.
41. Aparasu, RR., & Fliginger, SE.(1997). Inappropriate medication prescribing for the elderly by office-based physicians. *Annals of Pharmacotherapy*, 31, 7-8, 823-829.
42. Page, J., & Henry, D.(2000). Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An under recognized public health problem. *Archives of Internal Medicine*, 160, 6, 777-784.
43. Singh, G. (1998). Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. *American Journal of Medicine*, 105, 31S- 38S.
44. Graber, M, Gordon, R., & Franklin, N. (2002). Reducing diagnostic errors in medicine: What's the goal? *Quality and Safe Health Care*, 11, 258-260.
45. Gebhart, F.(2002). Is standard dosing to blame for adverse drug reactions? *Drug Topics*, January Issue.
46. Borzo, G.(2000). Medication errors initiative spotlights physicians. *OB/GYN News*, November 15, 2000.
47. Lesar, TS., Lomaestro, BM., & Pohl H.(1997). Medication prescribing errors in a teaching hospital: A 9 year experience. *Archives of Internal Medicine*, 157, 14, 1589-1576.

48. Hughes, CM., Honig, P., Phillips, J., Woodcock, J., Anderson, RE., McDonald, CJ., Weiner, M., & Hui, SL. (2002). How Many Deaths Are Due to Medical Errors? *Journal of The American Medical Association*, 284: 2187.
49. Epstein, RM. & Hundert, EM., (2002). Defining and Assessing Professional Competence. *Journal of The American Medical Association*, 287, 226-235.
50. McDonald, CJ., Weiner, M., & Hui, SL. (2002). Deaths Due to Medical Errors Are Exaggerated in Institute of Medicine Report, *Journal of The American Medical Association*, 284, 93-95.
51. Selim, K. & Kaplowitz, N. (1999). Hepatotoxicity of psychotropic drugs. *Hepatology*, 29, 5, 1347-1351.
52. Thomas, EJ & Brennan, TA. (2000). Incidence and types of preventable adverse events in elderly patients: Population based review of medical records. *British Medical Journal*, 320, 741-744.
53. Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001). Effectiveness of second generation antipsychotics in patients with treatment resistant schizophrenia: A review and meta-analysis of randomized trials. *American Journal of Psychiatry*, 158, 4, 518-526.
54. Volvavka, J., Czobor, B., Sheitman, J, Lindenmayer, L., Citrome, J., & Lieberman, J. (2002). Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. *American Journal of Psychiatry*, 159, 2, 255-262.
55. Moynihan, R. (2003). The making of a disease: Female sexual dysfunction. *British Medical Journal*, 326, 45-47.
56. Sclar, DA. (1998). Trends in the prescribing of antidepressant pharmacotherapy: Office based visits, 1990-1995. *Clinical Therapy*, 20, 4, 871-874.
57. McCarthy, AM. (2000). School medication errors. *Journal of School Health*, 70, 9, 371-376.

58. Honigfield, G. (1996). Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. *General Psychiatric Service*, 47, 1, 52-56
59. Mossman, D., & Lehrer, DS.(2000). Conventional and atypical antipsychotics and the evolving standard of care. *Psychiatric Service*, 51, 12, 1528-1535.
60. Glassman, AH & Bigger, JT.(2001). Antipsychotic drugs: Prolonged QT interval, torsade de pointes, and sudden death. *American Journal of Psychiatry*, 158, 1774-1782.
61. Steel, K. (2004). The time to act is now. *Archive Internal Medicine*, 164, 1603-1604.
62. Wiggins, JG. & Cummings, NA. (1998) National study of the experience of psychologists with psychotropic medication and psychotherapy. *Professional Practice*, 29, 6, 549-552.
63. American College of Neuropsychopharmacology (1998). DoD prescribing psychologists: External analysis, monitoring, and evaluation of the program and its participants. Final Report, May, 1998.
64. Bissinger, RL.(1997). A cost effectiveness analysis of neonatal nurse practitioners. *Nursing Economics*, 15, 92-99.
65. Giacalone, MB (1995). Practice model: Development of a nurse-managed unit and the advanced practitioner role. *Critical Care Nursing Clinics of North America*, 7, 35-40.
66. Martin, B, Coniglio, J. (1996). The acute care nurse practitioner in collaborative practice. *AACN Clinical Issues*, 7, 309-314.
67. Goldberg, D. P., T. Jenkins, T. Millar, and E. B. Faragher.(1993). The ability of trainee general practitioners to identify psychological distress among their patients. *Psychological Medicine*, 23, 1, 185-93.
68. Yasuda, S.( 2002). Adverse drug reaction curriculum missing at many medical schools. *Psychopharmacology Update*, April, 2002.

69. Curtis, L.H., Ostbye, T., Sendensky, V., Hutchinson, S., Dans, P.E., Wright, A., Woosley, R.L., & Schulman, K.A. (2004). Inappropriate prescribing for elderly Americans in a large outpatient population. *Archives Internal Medicine*, 164, 1621-1625.
70. Norfleet, MA (2002). Responding to societies needs: Prescription privileges for psychologists. *Journal of Clinical Psychology*, 58, 6, 599-610.
71. Harris Interactive (2004). Therapy in America Survey. *Psychology Today*, April Issue.
72. Cassano, GB. (1999). Suicide prevention—The global context. *American Journal of Psychiatry*, 156, 966a-967a.
73. Clark D, Horton-Deutsch S. (1992). Assessment in absentia: the value of the psychological autopsy method for studying antecedents of suicide and predicting future suicides. In: *Assessment and Prediction of Suicide*, Maris RW, Berman AL, Maltzberger JT, Yufit RI, eds. New York, Guilford, pp 144-182.
74. Caccavale, J. (2002). Opposition to prescriptive authority: Is this the case of the tail wagging the dog? *Journal of Clinical Psychology*. 2002; 58, 6:623-633.
75. Erlangsen1, A, Canudas-Romo, V, and Conwell, Y. Increased use of antidepressants and decreasing suicide rates: a population-based study using Danish register data. *Epidemiol Community Health* 2008;62:448-454 doi:10.1136/jech.2007.061580.
76. National Center for Health Statistics (NCHS), *Self-Inflicted Injury/Suicide* (Hyattsville, MD: NCHS, 2006), accessed online at [www.cdc.gov](http://www.cdc.gov), on July 17, 2006.
77. Scully JH. Why be concerned about recruitment? *Am J Psychiatry*. Oct 1995;152(10):1413-1414.
78. Sierles FS, Taylor MA. Decline of U.S. medical student career choice of psychiatry and what to do about it. *Am J Psychiatry*. Oct 1995;152(10):1416-1426.
79. Hales D. Recruiting psychiatrists seen as vital issue. *Psychiatr News*. Apr 4 1980;15(7):1, 4-5, 27.



80. Bacon TJ, Stallings KD. Workforce demands of mental health reform. *N C Med J*. Sep-Oct 2003;64(5):231-232.
81. Goldman W. Economic grand rounds: Is there a shortage of psychiatrists? *Psychiatr Serv*. Dec 2001;52(12):1587-1589.
82. APA Resident Census. Washington D, American Psychiatric Association, 1990-1999.
83. Many psychiatrists wouldn't choose medicine again-growing frustration, shrinking net pay creates 'Silent Shortage' of psychiatrist *Medical News Today*. 12 January 2006.
84. Scully JH, Wilk JE. Selected characteristics and data of psychiatrists in the United States, 2001-2002. *Acad Psychiatry*. Winter 2003;27(4):247-251.
85. Talbott C. Shortage of doctors affect rural U.S. *Associated Press*. July 21 2007.
86. McRee T, Dower C, Biggance B, Vance J, Keane D, O'Neil E. The mental health workforce: Who's meeting California's needs? Workforce Initiative at UCSF Center for the Health Professions. San Francisco: University of California, San Francisco; 2003.
87. Therapy in America. *Psychology Today*. 2004(August).
88. Eisenberg D, Bellows N, Brown T. Measuring mental health in California's Counties: What can we learn? The Nicolas C. Petris Center on Health Care Markets and Consumer Welfare. Berkeley: University of California, Berkeley 2005.
89. California Health Planning Council. Projected Fulltime Equivalent Positions and Vacancies. Statewide Overview Table. 2004.
90. Kanapaux W. Child Psychiatry Faces Workforce Shortage. *Psychiatric Times*. 2004;XXI(3).
91. Child, Geriatric Psychiatrists Worry About Workforce. *Psychiatric News*. 2003;38(7).
92. Olfson M, Shea S, Feder A, et al. Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice. *Arch Fam Med*. Sep-Oct 2000;9(9):876-883.

93. Lieberman JA. History of the use of antidepressants in primary care. *Journal of Clinical Psychiatry*. 2003;5(Sppl 7):6-10.
94. Leon AC, Portera L, Olfson M, et al. Diagnostic errors of primary care screens for depression and panic disorder. *Int J Psychiatry Med*. 1999;29(1):1-11.
95. Lefevre F, Reifler D, Lee P, et al. Screening for undetected mental disorders in high utilizers of primary care services. *J Gen Intern Med*. Jul 1999;14(7):425-431.
96. Beardsley RS, Gardocki GJ, Larson DB, Hidalgo J. Prescribing of psychotropic medication by primary care physicians and psychiatrists. *Arch Gen Psychiatry*. Dec 1988;45(12):1117-1119.
97. Pincus HA, Tanielian TL, Marcus SC, et al. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. *JAMA*. Feb 18 1998;279(7):526-531.
98. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. *JAMA*. Jul 21 2004;292(3):338-343.
99. Hodges B, Inch C, Silver I. Improving the psychiatric knowledge, skills, and attitudes of primary care physicians, 1950-2000: a review. *Am J Psychiatry*. Oct 2001;158(10):1579-1586.
100. Jones LR, Badger LW, Ficken RP, Leeper JD, Anderson RL. Inside the hidden mental health network. Examining mental health care delivery of primary care physicians. *Gen Hosp Psychiatry*. Jul 1987;9(4):287-293.
101. Giron M, Sanchez Garcia E, Fernandez Fernandez-Yanez A. [Efficacy of a clinical interview training technique and psychodiagnostic ability of the physician]. *Aten Primaria*. Feb 15 1998;21(2):115-116.
102. Schwenk T. Depression: overcoming barriers to diagnosis. *Consultant*. 1994;34:1553-1559.
103. Alarcon FJ, Isaacson JH, Franco-Bronson K. Diagnosing and treating depression in primary care patients: looking beyond physical complaints. *Cleve Clin J Med*. May 1998;65(5):251-260
104. Sierles FS, Dinwiddie SH, Patroi D, Atre-Vaidya N, Schrift MJ, Woodard JL. Factors affecting

medical student career choice of psychiatry from 1999 to 2001. *Acad Psychiatry*. Winter 2003;27(4):260-268.

105. Sierles FS, Yager J, Weissman SH. Recruitment of U.S. medical graduates into psychiatry: reasons for optimism, sources of concern. *Acad Psychiatry*. Winter 2003;27(4):252-259.

106. California Psychiatric Association: Policy Statement on Access to Psychiatric Services. 6/29/2002.

107. Rosack J. SSRI Prescriptions to Youth On Decline Since February. *Psychiatr News*. October 15, 2004 2004;39(20):9-32.

107a. Oxman TE, Dietrich AJ, Schulberg HC. Evidence-based models of integrated management of depression in primary care. *Psychiatr Clin North Am*. Dec 2005;28(4):1061-1077.

108. Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. *Bmj*. Feb 3 2007;334(7587):242.

109. Dubicka B, Hadley S, Roberts C. Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis. *Br J Psychiatry*. Nov 2006;189:393-398.

110. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Mann JJ. Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. *Am J Psychiatry*. Jul 2007;164(7):1044-1049.

111. Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. *Am J Psychiatry*. Nov 2006;163(11):1898-1904.

112. Jick H, Kaye JA, Black C. Incidence and prevalence of drug-treated attention deficit disorder among boys in the UK. *Br J Gen Pract*. May 2004;54(502):345-347.

113. Olfson M, Gameroff MJ, Marcus SC, Jensen PS. National trends in the treatment of attention deficit hyperactivity disorder. *Am J Psychiatry*. Jun 2003;160(6):1071-1077.

114. Safer DJ. Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990s. *J Child Adolesc Psychopharmacol*. 1997;7(4):267-274.

115. Wysowski DK. Surveillance of prescription drug-related mortality using death certificate data. *Drug Saf.* 2007;30(6):533-540.
116. Agelink MW, Majewski T, Wurthmann C, et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. *J Clin Psychopharmacol.* Feb 2001;21(1):8-13.
117. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. *Am J Psychiatry.* Sep 2004;161(9):1709-1711.
123. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. *J Clin Psychiatry.* 2007;68 Suppl 1:20-27.
118. Conley RR, Kelly DL. Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. *Psychopharmacol Bull.* 2007;40(1):77-97.
119. Neuroleptics: increased rate of venous thromboembolic events. *Prescrire Int.* Dec 2006;15(86):224.
120. Gareri P, De Fazio P, De Fazio S, Marigliano N, Ferreri Ibbadu G, De Sarro G. Adverse effects of atypical antipsychotics in the elderly: a review. *Drugs Aging.* 2006;23(12):937-956.
121. Ried LD, Renner BT, McConkey JR, Bengtson MA, Lopez LM. Increased cardiovascular risk with second-generation antipsychotic agent switches. *J Am Pharm Assoc* (2003). Jul-Aug 2006;46(4):491-498; quiz 499-501.
122. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. *J Clin Psychiatry.* Apr 2006;67(4):575-583.
123. Olsen KM. Pharmacologic agents associated with QT interval prolongation. *J Fam Pract.* Jun 2005; Suppl:S8-S14.
124. Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C. Prolactin levels during long-term risperidone treatment in children and adolescents. *J Clin Psychiatry.* Nov 2003;64(11):1362-1369.

125. Holroyd KA, O'Donnell FJ, Stensland M, Lipchik GL, Cordingley GE, Carlson BW. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial. *JAMA*. May 2 2001;285(17):2208-2215.
126. Paykel ES. Psychotherapy, medication combinations, and compliance. *J Clin Psychiatry*. 1995;56 Suppl 1:24-30.
127. Walsh BT, Wilson GT, Loeb KL, et al. Medication and psychotherapy in the treatment of bulimia nervosa. *Am J Psychiatry*. Apr 1997;154(4):523-531.
128. Dimidjian S, Hollon SD, Dobson KS, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. *J Consult Clin Psychol*. Aug 2006;74(4):658-670.
129. Jacobson NS, Hollon SD. Cognitive-behavior therapy versus pharmacotherapy: Now that the jury's returned its verdict, it's time to present the rest of the evidence. *J Consult Clin Psychol*. Feb 1996;64(1):74-80.
130. Weisz JR, Jensen PS. Efficacy and effectiveness of child and adolescent psychotherapy and pharmacotherapy. *Ment Health Serv Res*. Sep 1999;1(3):125-157.
131. Drake RE, Mercer-McFadden C, Mueser KT, McHugo GJ, Bond GR. Review of integrated mental health and substance abuse treatment for patients with dual disorders. *Schizophr Bull*. 1998;24(4):589-608.
132. Goldman W, McCulloch J, Cuffel B, Zarin DA, Suarez A, Burns BJ. Outpatient utilization patterns of integrated and split psychotherapy and pharmacotherapy for depression. *Psychiatr Serv*. Apr 1998;49(4):477-482.
133. DoD prescribing psychologists: External analysis, ACNP Evaluation Panel Report. May 1998.
134. Sammons MT, Gorny SW, Zinner ES, Allen RP. Prescriptive authority for psychologists: A consensus of support. *Prof Psychol: Resea Practice*. 2000;31(6):604-609.
135. Ramirez BJ. Opinions and attitudes of psychologists on obtaining prescription privileges.

Unpublished Doctoral Dissertation. 2002;Wright State University, School of Professional Psychology, Dayton Ohio.

136. Sechrest L, Coan JA. Preparing psychologists to prescribe. *J Clin Psychol.* Jun 2002;58(6):649-658.

137. American Psychological Association (1992). Report of Ad Hoc Task Force on Psychopharmacology. Washington DC.

138. Probst, J.C., Laditka, S., Moore, C.G., Harun, N. and Powell, M.P. (2005). Depression in rural populations: Prevalence, effects on life quality and treatment-seeking behavior. Office of Rural Health Policy, US Department of Health and Human Services, Rockville, MD.

139. Babyak, M., Blumenthal, J. A., et al. (2000). Exercise treatment for major depression: Maintenance of therapeutic benefit at 10 months. *Psychosomatic Medicine*, 62, 644-638.

140. Begley, S. The Depressing News About Antidepressants. *Newsweek*, January 9, 2010.

141. Benmansour, S., Cecchi, M., Morilak, D. A., Gerhardt, G. A., Javors, M. A., Gould, G. G., & Frazer, A., (1999). Effects of Chronic Antidepressant treatment on Serotonin Transporter Function, Density, and mRNA Level. *Journal of Neuroscience*. 19: 10494-10501.

142. Brown, E. S., Vigil, L., et al. (2005). A randomized trial of Citalopram versus placebo in outpatients with asthma and major depressive disorder: A proof of concept study. *Biological Psychiatry*.

143. Craighead, W. E., Craighead, L. W., Ilardi, S. S. (1998). Psychosocial Treatments for Major Depressive Disorder. In, Nathan, P., & Gorman, J. M. (Eds), *A guide to treatments that work*. Oxford University Press, New York.

144. Dobson, K.S. & Jackman-Cram, S. (1996). Common change Processes in Cognitive-Behavioral Therapies for Depression. In Dobson, K.S., & Craig, K.D. (Eds.), *Advances in Cognitive Behavioral Therapy*. Sage Publications, London.

145. Dobson, K.S. (1989). A meta-analysis of the efficacy of cognitive therapy for depression. *Journal of Consulting and Clinical Psychology*, 57: 414-419.
146. Elkin, I. (1990). NIMH treatment of depression collaborative research program. *Archives of General Psychiatry*. 47: 682-688.
147. Elkin, I., Shea, T., Watkins, J.T., Imber, S.D., Sotsky, S.M., Watkins, J.T., Collins, J.F., Glass, D.R., Pilkonis, P.A., Leber, W.R., Docherty, J.P., Fiester, S.J., & Parloff, M.B. (1992). Course of depressive symptoms over follow-up: Findings from the national institute of mental health treatment of Depression Collaborative Research Program. *Archives of General Psychiatry*. 41: 33-41.
148. Fava, G., (2003). Can long-term treatment with antidepressant drugs worsen the course of depression? *Journal of Clinical Psychiatry*. 64: 57-61
149. Fava, G. (1999). Potential sensitizing effects of antidepressant drugs on depression. *CNS Drugs*. 12: 247-256.
150. Fournier, J, DeRubeis, RJ, Hollon, Amsterdam, JD; Shelton, RC, & Fawcett, J.(2010). Antidepressant Drug Effects and Depression Severity A Patient-Level Meta-analysis. *JAMA*, Vol. 303 No. 1, January 6, 2010.
151. Greenberg, R. P.; Dornstein, R., et al (1994). A meta-analysis of fluoxetine outcome in the treatment of depression. *Journal of Nervous & Mental Disorder*, 182, 547-551, 549.
152. Greenfield, Susan, (1995). *Journey to the Centers of the Mind*. W. H. Freeman and Company, New York, New York.
153. Haddad, P., (1998). Antidepressants discontinuation reactions. *British Medical Journal*. 316: 1105-1106.
154. Hales, R. (1999). Editor, *Textbook of Psychiatry*. Washington, D.C.: American Psychiatric Press, 525.

155. Hobson, J. A., and Leonard, J. A. (2001). *Out of Its Mind: Psychiatry in Crisis, A Call for Reform*. Perseus Books Group, Cambridge MA.
156. Imel, Z.E., Melante, B.M., McKay, K.M., & Wampold, B.E. (2008). A Meta-Analysis of Psychotherapy and Medication in Unipolar Depression and Dysthymia. *Journal of Affective Disorders*, 110: 197-206.
157. Khan, A., Warner, H. A., & Brown, W. A. (2000). Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database. *Archives of General Psychiatry*, 57, 311-317.
158. Khan, W., & Brown, W. A. (2002). Are placebo controls necessary to test new antidepressants and anxiolytics: *International Journal of Neuropsychopharmacology*, 5, 193-197.
159. Kirsch, I. (2010). *The Emperor's New Drugs: Exploding the Antidepressant Myth*. Basic Books, New York.
160. Kline, D. (1994). Editorial, *Psychiatric News*, May 20, 1994.
161. Jackson, G. E. (2005). *Rethinking Psychiatric Drugs: A guide for informed consent*. Authorhouse, Bloomington, Indiana.
162. Laughren, T. P. (March 26, 1998). Recommendations for approval action for Celexa (Citalopram) for the treatment of depression: Memorandum: Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for drug evaluation Research, Washington, D. C. p. 9.
163. Leuchter, A. F., Cook, I. A., Witte, E. A., Morgan, M., & Abrams, M. (2002). Changes in brain function of depressed subjects during treatment with placebo. *American Journal of Psychiatry*, 159, 122-129.
164. Lesch, K.P., Aulakh, C.S., Wolozin, B.L., Tolliver, T.J., Hill, J.L., (1993). Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants.



*Molecular Brain Research. 17: 31-35.*

165. Parker, G. (2009). Antidepressants on trial, *British Journal of Psychiatry.* 194: 1-3.
166. Prator, B.C. (2006). Serotonin Syndrome. *Journal of Neuroscience Nursing.* 38: no. 2, 102-105.
167. Prien, R. (1984). Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. *Archives of General psychiatry.* 41: 1096-1104.
168. Raskin, A. (1970). Differential response to chlorpromazine, imipramine, and placebo. *Archives of General Psychiatry.* 23; 164-173.
169. Roose, S. P., Sackeim, H. A., et al. (2004). Antidepressant pharmacotherapy in the treatment of depression in the very old: A randomized, placebo-controlled trial. *American Journal of Psychiatry,* 161, 2050-2059, p. 2050.
170. Schneider, L. S., Nelson, J. C, et al. (2003). An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. *American Journal of Psychiatry,* 160, 1277-1285.
171. Scott, T. (2006). *America Fooled: The Truth About Antidepressants, Antipsychotics, and How We've been Deceived.* Argo Publishing, LLC., Victoria Texas.
172. Shea, M. (1992). Course of depressive symptoms over follow-up. *Archives of General Psychiatry.* 49: 782-787.
173. Shea, M.T., Elkin, I., Imber, S.D., Sotsky, S.M., Watkins, J.T., Collins, J.F., Pilkonis, P.A., Beckham, E., Glass, D.R., Dolan, R.T., & Parloff, M.B. (1992). Course of depressive symptoms over follow-up: Findings from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. *Archives of General Psychiatry.* 46: 971-982.
174. Smith, A. (1969). Studies on the effectiveness of antidepressant drugs. *Psychopharmacology Bulletin* 5, 1-53.

175. Stein, M. (1980). Maintenance therapy with amitriptyline. *Archives of General Psychiatry*. 49: 782-787.
176. Schwartz, Jeffery, and Begley, Sharon (2002). *The Mind & The Brain: Neuroplasticity and the Power of Mental force*. HarperCollins Publishers, New York, New York.
177. Thomson, R., (1982). Side effects and placebo amplification. *British Journal of Psychiatry* 140: 64-68.
178. Turner, E. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. *New England Journal of Medicine*. 358: 252-260.
179. U.S. Congress. House of Representatives. Committee on Energy and Commerce. *Publication and Disclosure Issues in Antidepressant Pediatric Clinical Trials: Hearing Before the Subcommittee on Oversight and Investigations*. 99<sup>th</sup> Congress, 2<sup>nd</sup> Session, Sept. 9, 2004, p. 7. Available at web site <http://www.access.gpo.gov/congress/house>.
180. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med*;358:252-60.
181. United States Senate Special Committee on Aging. (2009, Wednesday, January 14, 2009). Bolstering Workforce Will Be Integral Part of National Health Care Reform [Press release]. Retrieved from <http://aging.sena>
182. Van Scheyen, J.D. (1973). Recurrent vital depressions. *Psychiatria, Neurologia, Neurochirurgia*. 76: 93-112.
183. Wagner, K. D., Ambrosini, P, et al. (2003). Efficacy of Sertraline in the treatment of children and adolescents with major depressive disorder. *Journal of the American Medical Association*, 290, 1033-1041.
184. Whitaker, R., (2010). *Anatomy of an Epidemic*. Crown Publishers, New York.

185. Tarn, Dm; Paterniti, DA; Heritage, J; Hays, RH; Kravitz, RL; and Wenger, N. Physician Communication About the Cost and Acquisition of Newly Prescribed Medications. Arch Intern Med 2006;1855-1862.
186. Femrite v. Abbot NW Hospital (1997 Minn.) 568 N.W.2d 535, 540; 51 in Nightingale, S.L., Use of Drugs for Unlabeled Indications, American Family Physician, 269 September 1986, Nightingales, S.L., Unlabeled Use of Approved Drugs, Drug Information Journal, 26:141-147, 1992.
187. FDA Drug Bulletin (1982) 12:4-5.
188. For The Media. JAMA/Archives Journals, News release, Nov. 23, 2009
189. Kessler D, Lloyd K, Lewis G, Gray DPG, Heath I. Cross sectional study of symptom attribution and recognition of depression and anxiety in primary care. BMJ 1999; 318: 436-440.
190. Lewis G, Pelosi A, Glover E. The development of a computerised assessment for minor psychiatric disorder. Psychol Med 1988; 18: 737-745.
191. Baik, S.Y., Gonzales, JJ, Bowers, BJ, Anthony, B, Tidjani, B, and Susman, JL. Reinvention of Depression Instruments by Primary Care Clinicians. Annals of Family Medicine 8:224-230 (2010).
192. Website at [www.fsmb.org](http://www.fsmb.org),
193. Federation of State Medical Boards Special Committee on Maintenance of Licensure. Draft Report. Available at: [http://www.fsmb.org/grpol\\_SpecialCommittee.html](http://www.fsmb.org/grpol_SpecialCommittee.html). Accessed Jan 29, 2008.
194. Alliance for Physician Competence. Good Medical Practice-USA, Draft #1, Jan 10, 2007. Presented for discussion at the Physician Accountability for Physician Competence Summit IV, St. Petersburg, Fla., Jan 14-16, 2007. Available at: <http://www.innovationlabs.com/summit/summit4/>. Accessed Jan 29, 2008.
195. National licensure? AAPS News 2007;63(3):2.

195a. [http://www.acponline.org/running\\_practice/pcmh/understanding/index.html](http://www.acponline.org/running_practice/pcmh/understanding/index.html)

195b. Turner, E., Matthews, AM, Linardatos, Tell, RA, and Rosenthal, R.  
Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy.  
*NEJM*, Volume 358:252-260, January 17, 2008, Number 3.

195c. McGauran, N, et al. Reporting Bias in Medical Research - A Narrative Review. Institute for Quality and Efficiency in Health Care, *Trials*, April 2010, 11:37.

196. AAPS. Comments on Draft report of the Special Committee on Maintenance of Licensure, Jan 7, 2007. Available at: <http://www.aapsonline.org/licensure/fsmbmol.php>. Accessed Jan 29, 2008.

197. Tarn, DM; Paterniti, DA; Heritage, J; Hays, RH; Kravitz, RL; and Wenger, N. Physician Communication About the Cost and Acquisition of Newly Prescribed Medications. *Arch Intern Med* 2006;1855-1862.

198. Olfson M, Crystal S, Huang C, Gerhard T. Trends in antipsychotic use by very young, privately insured children. *J Am Acad Child Psy* 2010;49:13-23.

199. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. *Health Aff (Millwood)* 2009;28:w770-781.

200. Moore, T. J. (1999, October 17). No prescription for happiness. *Boston Globe*, E01. Retrieved February 1,

2003, from <http://www.thomasjmoore.com/pages/prozpop.html>.

201. Rosenthal, R. (1979). The "file drawer problem" and tolerance for null results. *Psychological Bulletin*, 86, 638-641.

202. O'Brien, LM, Holbrook, CR, Mervis, CB, Klaus, CJ, Bruner, JB, Raffield, TJ, Rutherford, J, Mehl, RC, Wang, M, Tuell, A, Hume, BC, and Gozal, D. Sleep and Neurobehavioral Characteristics of 5- to 7-Year-Old Children With Parentally Reported Symptoms of Attention-Deficit/Hyperactivity

Disorder. *PEDIATRICS* Vol. 111 No. 3 March 2003, pp. 554-563.

203. Sadeh, A, Raviv, R, and Gruber, R. Sleep Patterns and Sleep Disruptions in School-Age Children. *Developmental Psychology*, Vol. 36, No. 3, 2008.

204. Gruber, R. Instability of Sleep Patterns in Children With Attention-Deficit . *Journal of the American Academy of Child & Adolescent Psychiatry*, Volume 39, Issue 4, Pages 495-501, April 2000

205. Committee on Quality Improvement, Subcommittee on Attention Deficit/Hyperactivity Disorder, American Academy of Pediatrics. Clinical Practice Guideline: Diagnosis and Evaluation of a child with ADHD. *Pediatrics* 2000;105(5):1158-70.

206. Marchetti, A, Magar, R., Lau H, Murphy, EL, Jensen , PS, Conners, K, Findling, R, Wineburg, E, Carotenuto, I, Einarson, TR, and Iskedjian, M. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. *Clinical Therapeutics*, Volume 23, Issue 11, November 2001, Pages 1904-1921.

207. Pharma Analysis. <http://m.industry.bnet.com/pharma/10005981/facing-stunted-growth-in-adhd-market-shire-clicks-on-twitter/>.

208. Weiss M, Safren SA, Solanto MV, Hechtman L, Rostain AL, Ramsay JR, Murray C. Research forum on psychological treatment of adults with ADHD. *Journal of Attention Disorders* 2008; 11(6): 642-651.

209. Solanto MV, Schachar R, Ickowicz A. The Psychopharmacology of ADHD. In: Fitzgerald M, Bellgrove MA, Gill M, editors. *Handbook of Attention Deficit Hyperactivity Disorder*. West Sussex, England, John Wiley & Sons, Ltd; pp269-314.

210. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. *Arch Gen Psychiatry* 1993;50:565-576.

211. Vanderschuren, LJM, Schmidt, ED, De Vries, TJ, Van Moorsel, CP, Tilders, F, and Schoffelmeer,

A. A Single Exposure to Amphetamine Is Sufficient to Induce Long-Term Behavioral, Neuroendocrine, and Neurochemical Sensitization in Rats. *The Journal of Neuroscience*, November 1, 1999, 19(21):9579-9586.

212. Gainetdinov, RJ, Wetsel, WC, Jones, SR, Levin, ED, Jaber, M, and Caron, MC. Role of Serotonin in the Paradoxical Calming Effect of Psychostimulants on Hyperactivity. *Science* 15 January 1999: Vol. 283. no. 5400, pp. 397 - 401.

213. Ford, AJ. Nonmedical Prescription Drug Use Among Adolescents: The Influence of Bonds to Family and School. *Youth Society*, March 1, 2009; 40(3): 336 - 352.

214. Alemagno, SA, Stephens, P., Shaffer-King, P., and Teasdale, B. Prescription Drug Abuse Among Adolescent Arrestees: Correlates and Implications *Journal of Correctional Health Care*, January 1, 2009; 15(1): 35 - 46.

214a. Cummings, NA and Wiggins, JG. A Collaborative Primary Care/Behavioral Health Model for the Use of Psychotropic Medication With Children and Adolescents. *Issues In Interdisciplinary Care*, Vol. 3, No. 2, April 2001, 121-128.

215. Ellison, K. Medical Marijuana Prescribed to Kids with ADHD. *New York Times*; November 22, 2009.

216. Grinspoon, L. & Bakalar, J.B. *Marihuana: The Forbidden Medicine*. *Yale University Press*; 1997.

217. Caccavale, JL. Should Marijuana Be Considered An Appropriate Treatment For ADD/ADHD In Children and Adolescents? *National Psychologist*, February, 2010.

218. Harris, J. Child & Adolescent Psychiatry: The Increased Diagnosis of "Juvenile Bipolar Disorder": What Are We Treating? *Psychiatr Serv* 56:529-531, May 2005.

219. Barbara Geller, Betsy Zimmerman, Marlene Williams, Melissa P. DelBello, Jeanne Frazier, Linda

Beringer. *Journal of Child and Adolescent Psychopharmacology*. March 2002, 12(1): 3-9.  
doi:10.1089/10445460252943524.

220. L. Faedda, Ross J. Baldessarini, Trisha Suppes, Leonardo Tondo, Ina Becker, and Deborah S. Lipschitz. Perinatal-Onset Bipolar Disorder: A Neglected Clinical and Public Health Problem. *Harvard Review of Psychiatry*, 1995, Vol. 3, No. 4, Pages 171-195.

221. Berard, A, Einarson, A, and Yasin, S. Risk of Miscarriage Linked to Antidepressants. *Canadian Medical Association Journal*, May, 2010.

222. Stopping antidepressant use while pregnant may pose risks. National Institute of Mental Health. <http://www.nimh.nih.gov/science-news/2006/stopping-antidepressant-use-while-pregnant-may-pose-risks.shtml>. Accessed Aug. 20, 2009.

223. Louik C, et al. First-trimester use of selective serotonin reuptake inhibitors and the risk of birth defects. *The New England Journal of Medicine*. 2007;356:2675.

224. Suri R, et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and preterm birth. *The American Journal of Psychiatry*. 2007;164:1206.

225. Sackett JC, et al. Selective serotonin reuptake inhibitor use during pregnancy and possible neonatal complications. *Current Psychiatry Reports*. 2009;11:253.

226. The American College of Obstetricians and Gynecologists Committee on Practice Bulletins - Obstetrics. Use of psychiatric medications during pregnancy and lactation. *ACOG Practice Bulletin*. 2008;92:1.

227. Clemens, N.A. New Parity, Same Old Attitude Towards Psychotherapy? *Journal of Psychiatric Practice*: March 2010 - Volume 16 - Issue 2 - pp 115-119.

228. Los Angeles Times, Psychotherapy Use On The Wane; Psychiatrists Increasingly Turning To Antidepressants And Other Prescription Medications. August 5, 2008.

229. Goldman, W., McCulloch, J., and Sturm, R. Costs And Use Of Mental Health Services Before And After Managed Care. *Healthaffairs*, Vol. 17, No. 2. 1998.
230. S.S. Sharfstein, "Utilization Management: Managed or Mangled Psychiatric Care?" *American Journal of Psychiatry* 147, no. 8 (1990): 965–966; and G.L. Tischler, "Utilization Management of Mental Health Services by Private Third Parties," *American Journal of Psychiatry* 147, no. 8 (1990): 967–973.
231. Frank, R. G., & Shore, M. F. (1996). Performance measures for managed behavioral healthcare programs: PERMS 1.0. Washington, DC: American Behavioral Healthcare Association.
232. Mental Health: A Report of The Surgeon General. 1999.
233. Rand Corporation. Research Highlights. How Does Managed Care Affect the Cost of Mental Health Services? RB-4515, (1998).
234. McPherson, RH, Elman, NS, Crosbie-Burnett, M, and Sayger, TV. The Counseling Psychologist, Vol. 28 No. 5, September 2000 687-700.
235. Carroll, J. Phantom' Provider Panels Get Attention of States, NCQA. *Managed Care Magazine*, July, 2002.
236. Cummings, NA, O'Donohue, WO, and Cummings, JL. The Financial Dimension of Integrated Behavioral/Primary Care. *J Clin Psychol Med Settings*, January 2009.
237. American Geriatrics Society and American Association for Geriatric Psychiatry, (2003). The American Geriatrics Society and American Association for Geriatric Psychiatry recommendations for policies in support of quality mental health care in U.S. nursing homes. *Journal of the American Geriatrics Society*, 51, 1299-1304.
238. AHCA, [http://www.ahcancal.org/research\\_data/staffing/Documents/WorkforceAtAGlance.pdf](http://www.ahcancal.org/research_data/staffing/Documents/WorkforceAtAGlance.pdf)
239. American Hospital Association, <http://www.aha.org/aha/research-and-trends/index.html>



240. Centers for Disease Control and Prevention. (2004). *National hospital discharge survey*. (NCHS Data Set CC36.NHDS04). Hyattsville, MD: National Center for Health Statistics
241. Chiles, J.A., Lambert, M.J., Hatch, A.L. (1999). The impact of psychological interventions on medical cost offset: A meta-analytic review. *Clinical Psychology: Science and Practice*, 6, 204-220.
242. Department of Health and Human Services, Office of Inspector General. (2001). *Psychotropic Drug Use in Nursing Homes*, Nov. 2001, OEI 02-00-00490
243. Disease Management Association of America, <http://www.dmaa.org/>
244. Fan, V.S., Ramsey, S.D., Giardino, N.D., Make, B.J., Emery, C.F., Diaz, P.T., Benditt, J.O., Mosenifar, Z., McKenna, R., Curtis, J.L., Fishman, A.P., & Martinez, F.J. (2007). Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. *Archives of Internal Medicine*, 167, 2345 - 2353.
245. Gatz, M., Karel, J.J., & Wolkenstein, B. (1991). Survey of providers of psychological services to older adults. *Professional Psychology: Research and Practice*, 22, 413-415.
246. Golden, S.H., Lazo, M., Carnethon, M., Bertoni, A.G., Schreiner, P.J., Diez Roux, A.V., Lee, H.B., Lyketos, C. (2008). Examining a bidirectional association between depressive symptoms and diabetes. *Journal of the American Medical Association*, 299(23), 2751-2759.
247. Hamberger, L.K., Ovide, C.R., Weiner, E.L. (1999). *Making Collaborative Connections with Medical Providers*. New York: Springer.
248. Institute of Medicine. 2008. *Retooling for an aging America: Building the health care workforce*. Washington, D.C.: National Academies Press.
249. Jeste, D.V., Alexopoulos, G.S., Barrels, S.J. (1999). Consensus statement on the upcoming crisis in geriatric mental health: Research agenda for the next 2 decades. *Archives of General Psychiatry*, 56, 848-853.

250. Levant, R.F. (2005). Psychological approaches to the management of health and disease: Health care for the whole person. In N.A. Cummings, W.T. O'Donohue, & E.V. Naylor (Eds.), *Psychological Approaches to Chronic Disease Management*. Reno, Nevada: Context Press.
251. McGinnis, J.M., & Foege, W.H. (1993). Actual causes of death in the United States. *Journal of the American Medical Association*, 270, 2207-2212.
252. National Center for Health Statistics. (June, 2009). *National Nursing Home Survey 2004 Overview*, U.S. Department of Health and Human Services, Centers for Disease Control.
253. Prevention. DHHS Publication No. (PHS) 2009-1738.
254. Sbordone, R.J. and Serman, L.T. (1983). The psychologist as a consultant in a nursing home; Effect on staff morale and turnover. *Professional Psychology Research and Practice*, 14, 240-250.
255. Thombs, B.D., Ziegelstein, R.C., Stewart, D.E., Abbey, S.E., Parakh, K., Grace, S.L. (2007). Usefulness of persistent symptoms of depression to predict physical health status 12 months after an acute coronary syndrome. *American Journal of Cardiology*, 101(1), 15-19.
256. Laroche, ML, Charmes,JP, Nouaille, Y, Picard, N, and Merle, L. Is inappropriate medication use a major cause of adverse drug reactions in the elderly? *Br J Clin Pharmacol*. 2007 February; 63(2): 177-186.
257. Gallagher, PF, Barry, PJ, Ryan, C, Hartigan, I, and O'Mahony,D. Inappropriate prescribing in an acutely ill population of elderly patients as determined by Beers' Criteria. *Age and Aging* 2008 37(1):96-101.
258. Beers MH. Explicit criteria for determining inappropriate medication use by the elderly. An update. *Arch Intern Med*. 1997;157:1531-6.
259. Kim, T. S. Tofade, and H. Peckman. Caring for the Elderly in an Inpatient Setting: Managing Insomnia and Polypharmacy, *Journal of Pharmacy Practice*, October 1, 2009; 22(5): 494 - 506.

260. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. *JAMA* 1997;277(4):301-6.
261. Cullen DJ, Sweitzer BJ, Bates DW, et al. Preventable adverse drug events in hospitalized patients: A comparative study of intensive care and general care units. *Crit Care Med* 1997;25(8):1289-97.
262. Cullen DJ, Bates DW, Small SD, et al. The incident reporting system does not detect adverse drug events: A problem for quality improvement. *Journal on Quality Improvement* 1995;21(10): 541-8.
263. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. *JAMA* 1997;277(4):307-11.
264. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. *JAMA* 1995;274(1):29-34.
265. Raschke RA, Collihare B, Wunderlich TA, et al. A computer alert system to prevent injury from adverse drug events. *JAMA* 1998;280(15):1317-20.
266. Thomas EJ, Studdert DM, Newhouse JP, et al. Costs of medical injuries in Utah and Colorado. *Inquiry* 1999;36(3):255-64.